Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sartorius Stedim BiotechCHIX:DIMP 84 Equity-to-Asset is 0.54 as of Jun. 2026, which is 8% above its 10-year median of 0.50. GuruFocus rates CHIX:DIMP with a GF Score™ of 84/100 and a GF Value™ of €198.99 (Fairly Valued). The stock has 5 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks worse than 62.6% on this metric.
The historical rank and industry rank for Sartorius Stedim Biotech's Equity-to-Asset or its related term are showing as below:
CHIX:DIMp'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33 Med: 0.5 Max: 0.66
Current: 0.54
During the past 13 years, the highest Equity to Asset Ratio of Sartorius Stedim Biotech was 0.66. The lowest was 0.33. And the median was 0.50.
CHIX:DIMp's Equity-to-Asset is ranked worse than 62.6% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs CHIX:DIMp: 0.54
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Sartorius Stedim Biotech Equity-to-Asset Related Terms
Sartorius Stedim Biotech Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DIMP vs ISRG, BDX, MDLN: Equity-to-Asset Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Sartorius Stedim Biotech's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech (CHIX:DIMP) has a Equity-to-Asset of 0.54 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Sartorius Stedim Biotech and its competitors. This is near median its historical median of 0.50. Over the past decade, Sartorius Stedim Biotech's Equity-to-Asset has ranged from 0.33 to 0.66. According to the industry distribution chart, Sartorius Stedim Biotech ranks #534 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 62.6%.
Is Sartorius Stedim Biotech's Equity-to-Asset too high?
Sartorius Stedim Biotech's current Equity-to-Asset of 0.54 is near median its 10-year median of 0.50. Over the past 10 years, this metric has ranged from a low of 0.33 to a high of 0.66. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Sartorius Stedim Biotech's value of 0.54 is 15.6% below this industry median. Based on the distribution chart, Sartorius Stedim Biotech ranks #534 out of 853 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sartorius Stedim Biotech has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Equity-to-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #534 out of 853 companies for Equity-to-Asset. This places Sartorius Stedim Biotech in the lower half of its industry. The industry median Equity-to-Asset is 0.64. Sartorius Stedim Biotech's value of 0.54 is 15.6% below this benchmark. Historically, Sartorius Stedim Biotech's own Equity-to-Asset has ranged from 0.33 to 0.66 over the past decade. While the company's 10-year median is 0.50 vs. the industry median of 0.64, Sartorius Stedim Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current Equity-to-Asset of 0.54 is 15.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Sartorius Stedim Biotech and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current Equity-to-Asset is 0.54, which is near median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Fairly Valued. The stock's GF Value™ is €198.99, compared to a current price of €182.45 — trading 8.3% below its estimated fair value. The current Equity-to-Asset is 0.54, which is near median its 10-year median of 0.50 and 15.6% below the Medical Devices & Instruments industry median of 0.64. Sartorius Stedim Biotech's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current Equity-to-Asset is 0.54 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of €182.45 is trading 8.3% below its estimated GF Value™ of €198.99.
GuruFocus considers Sartorius Stedim Biotech to be Fairly Valued.
Key valuation signals for CHIX:DIMP:
Equity-to-Asset: 0.54 (near median its 10-year median of 0.50)
GF Value™: €198.99 vs. price of €182.45 (8.3% below fair value)
Industry Position: 15.6% below the Medical Devices & Instruments median (#534 of 853)
No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
84GF Score
Get the complete analysis for CHIX:DIMP
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIMP has been successfully added to your 
